CMC, Bioprocessing & Scale-Up Blog - Smart Biotech Scientist

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Data & Analytics

Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 2

What separates labs with truly connected, AI-ready data from those drowning in digital chaos?

Data & Analytics

Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 1

What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?

Bioprocessing

How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics

“Will this novel host replace CHO?” I hear this question often — and I want to be direct with you: I think it’s the wrong question.

Bioprocessing

Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts)

Is CHO still the host of choice?

Biotech Success

Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 2

Securing capital for biotech innovation has never been more challenging—or more crucial.

Biotech Success

Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 1

Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.

Bioprocessing

Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC

What if the difference between a seamless tech transfer and a costly setback isn’t your process, but how you orchestrate the people and details behind the scenes?

Bioprocessing

Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework

Tech transfer in biotech can feel like a high-stakes gamble, balancing regulatory shifts, incomplete data, and mounting stakeholder pressure—all with timelines breathing down your neck.

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 2

Are you struggling with the complexities of cell and gene therapy manufacturing and wondering how automation and digital solutions can truly make these life-saving therapies accessible to more people?

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 1

Cell and gene therapies have opened the doors to personalized medicine, but manufacturing these complex therapies is filled with hidden process risks that can compromise efficacy and patient access.

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 2

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

What if the secret to healthier, longer lives is quietly discarded in hospital operating rooms every day?

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2

T cell therapies promise life-changing outcomes for cancer patients, but their personalized, patient-specific nature throws a wrench into the classic centralized manufacturing playbook.

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1

Cell and gene therapies represent a revolutionary advance in personalized medicine, offering hope where traditional biologics and small molecules have struggled.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Dr. David Brühlmann

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Dr. David Brühlmann

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Dr. David Brühlmann

CMC and Bioprocess Blog

Data & Analytics

Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 2

Data & Analytics

Why AI and Automation Tools Won’t Deliver Until Your Lab’s Data Is Connected – Part 1

Bioprocessing

How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics

Bioprocessing

Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts)

Biotech Success

Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 2

Biotech Success

Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 1

Bioprocessing

Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC

Bioprocessing

Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 2

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 1

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 2

Innovation

How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers – Part 1

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 2

Innovation

How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) – Part 1

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.